| Drug ID: | Drug14 |
|---|---|
| Drug Name: | Ciprofloxacin |
| CID: | 2764 |
| DrugBank ID: | DB00537 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT01772615, , NCT00355602, , NCT02765256???CT00257699 |
| Molecular Formula: | C17H18FN3O3 |
| Molecular Weight: | 331.34 g/mol |
| Isomeric SMILES: | C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O |
| Synonyms: | ciprofloxacin; 85721-33-1; Ciprofloxacine; Ciprobay; Ciprofloxacina; Ciproxan; Ciprofloxacino; Ciprofloxacinum; Cipro IV; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid |
| Phase 0: | 7 |
| Phase 1: | 63 |
| Phase 2: | 61 |
| Phase 3: | 69 |
| Phase 4: | 69 |
| Description: | A broad-spectrum antimicrobial carboxyfluoroquinoline. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt120 | 2764 | Ciprofloxacin | 887105 | gyrA | Mycobacterium tuberculosis H37Rv | 23275348 | None |
| dt121 | 2764 | Ciprofloxacin | 581 | BAX | Homo sapiens (human) | None | |
| dt122 | 2764 | Ciprofloxacin | 1571 | CYP2E1 | Homo sapiens (human) | None | |
| dt123 | 2764 | Ciprofloxacin | None | -- | Haemophilus influenzae Rd KW20 | Inhibitor | |
| dt124 | 2764 | Ciprofloxacin | None | -- | Staphylococcus aureus | 37713619 | Modulator |
| dt125 | 2764 | Ciprofloxacin | 3643463 | CDC21 | Candida albicans SC5314 | 37713619 | Inhibitor |
| dt126 | 2764 | Ciprofloxacin | None | -- | Staphylococcus aureus | Modulator | |
| dt127 | 2764 | Ciprofloxacin | 7153 | TOP2A | Homo sapiens (human) | Inhibitor | |
| dt128 | 2764 | Ciprofloxacin | 3757 | KCNH2 | Homo sapiens (human) | 12873512 | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02765256 | Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease | PHASE2 | COMPLETED | University of Pennsylvania | Crohn's Disease | DRUG: Fluconazole|DRUG: Vancomycin|DRUG: Neomycin… | Details |
| NCT00257699 | Study of Antibiotics in the Treatment of Colonic Crohn's Disease | PHASE2 | TERMINATED | Mount Sinai Hospital, Canada | Crohn's Disease | DRUG: Metronidazole placebo|DRUG: ciprofloxacin p… | Details |
| NCT01772615 | Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle | PHASE4 | COMPLETED | Hvidovre University Hospital | Ulcerative Colitis | DRUG: Ciprofloxacin|DIETARY_SUPPLEMENT: E. coli N… | Details |
| NCT00355602 | Antibiotics for the Treatment of Ulcerative Colitis | None | COMPLETED | University of Dundee | Colitis, Ulcerative | DRUG: Cefuroxime|DRUG: Ciprofloxacin|DRUG: Clarit… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Persistent Colonization of Ciprofloxacin-Resistant and Extended-Spectrum β-Lact…
PMID: 38628240
Year: 2024
Relationship Type:
Association
Score: 6.5
OBJECTIVE: Salmonella enterica serovar Kentucky ST198 has emerged as a global threat to humans. In this study, we aimed to characterize the prolonged…
The Comparative Effectiveness of Ciprofloxacin and Metronidazole for an Initial…
PMID: 37463438
Year: 2023
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: There is minimal evidence regarding the comparative effectiveness of individual antibiotics in the treatment of pouchitis. We sought to…
Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Bud…
PMID: 32681228
Year: 2021
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Increased mucosa-associated E. coli are present in Crohn's disease, but their role in pathogenesis is uncertain. AIMS: To assess efficacy…
Increased Quinolone-Resistant Mutations of gyrA and parC Genes after Pouchitis …
PMID: 32182609
Year: 2020
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Oral antibiotics, such as ciprofloxacin (CFX), are widely used for the treatment of acute and chronic pouchitis. Most bacterial mutations…
Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active …
PMID: 24972748
Year: 2014
Relationship Type:
Treatment
Score: 6.3
BACKGROUND AND AIM: Ulcerative colitis (UC) is a chronic inflammatory bowel disease. The probiotic bacterium Escherichia coli Nissle 1917 (EcN) has b…
Ciprofloxacin usage and bacterial resistance patterns in Crohn's disease patien…
PMID: 24296421
Year: 2014
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Ciprofloxacin is the antibiotic most frequently used in the treatment of Crohn's disease (CD). We attempted to identify the microorganism…
Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in…
PMID: 23525574
Year: 2014
Relationship Type:
Treatment
Score: 6.3
OBJECTIVE: To assess whether a combination of adalimumab and ciprofloxacin is superior to adalimumab alone in the treatment of perianal fistulising C…
Ciprofloxacin for the prevention of postoperative recurrence in patients with C…
PMID: 23511031
Year: 2013
Relationship Type:
Treatment
Score: 6.1
BACKGROUND: The commensal bacterial flora plays a critical role in the postoperative recurrence of Crohn's disease (CD). We conducted a randomized, d…